Rigel Pharmaceuticals RIGL Delivery of drug supplies, royalties and others — Revenue recognized

Other product segments

Similar metrics at other companies

XER

XERSRoyalty, contract and other revenue — Product revenue, net

$673K-71.0%

RARECollaboration And Royalty — Revenue

$93M-9.7%

AQSTRoyalty — Revenue

$0—

ALKSRoyalty — Revenue

$50.73M+13.5%

SUPNRoyalty, licensing, and other revenues — Total revenues

$29.31M+274%

ETONProduct Sales And Royalties — Revenue

$24.27M+73.4%

Questions, answered.

What is Rigel Pharmaceuticals's delivery of drug supplies, royalties and others — revenue recognized?

Rigel Pharmaceuticals (RIGL) reported delivery of drug supplies, royalties and others — revenue recognized of $3.9M in Q1 2026.

How has Rigel Pharmaceuticals's delivery of drug supplies, royalties and others — revenue recognized changed year-over-year?

Rigel Pharmaceuticals's delivery of drug supplies, royalties and others — revenue recognized decreased by 42.6% year-over-year, from $6.78M to $3.9M.

What is the long-term trend for Rigel Pharmaceuticals's delivery of drug supplies, royalties and others — revenue recognized?

Over 4 years (2021 to 2025), Rigel Pharmaceuticals's delivery of drug supplies, royalties and others — revenue recognized has grown at a 55.0% compound annual growth rate (CAGR), from $3.3M to $19.05M.

What does delivery of drug supplies, royalties and others — revenue recognized mean?

This metric represents the revenue recognized from the sale of pharmaceutical products, royalty payments received from licensing agreements, and other related commercial activities. It captures the income generated from the company's core drug portfolio and the monetization of intellectual property through partnerships. This revenue stream is critical for assessing the company's ability to commercialize its pipeline and extract value from collaborative development agreements.